Related Experiment Video

Updated: Jun 12, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway

Mary L Hixon1, Luisa Paccagnella, Robert Millham

  • 1Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, USA.

Reviews on Recent Clinical Trials
|June 11, 2010
PubMed

Insights

Targeted cancer therapies show promise but face resistance due to pathway crosstalk. Combining inhibitors of pathways like IGF-IR/PI3K/Akt/mTOR may overcome resistance and improve efficacy in oncology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies inhibiting tyrosine kinases and signaling pathways are advancing cancer treatment.
  • Specific inhibitors are generally well-tolerated but can be limited by pathway cross-talk and feedback loops.
  • The Insulin-like Growth Factor-1 Receptor (IGF-IR)/PI3K/Akt/mTOR pathway exemplifies challenges in targeted therapy efficacy.

Purpose of the Study:

  • To explore strategies for combining targeted agents to overcome resistance mechanisms.
  • To investigate methods for preventing or delaying resistance to targeted therapies without increasing toxicity.
  • To evaluate the potential of combined IGF-IR, PI3K, Akt, and mTOR inhibition in cancer treatment.

Main Methods:

  • Review of current targeted agents and their mechanisms of action.
  • Analysis of pathway interactions, including cross-talk and feedback loops.
  • Examination of ongoing and planned clinical trials for IGF-IR, PI3K, Akt, and mTOR inhibitors.

Main Results:

  • Targeted agents are effective but can be circumvented by complex signaling networks.
  • Pathway cross-talk and feedback loop downregulation can limit the efficacy of single-agent therapies.
  • Combination therapies targeting multiple nodes within the IGF-IR/PI3K/Akt/mTOR pathway are under investigation.

Conclusions:

  • Combining targeted agents, particularly within the IGF-IR/PI3K/Akt/mTOR pathway, is crucial for overcoming resistance.
  • Further clinical evaluation of combined IGF-IR, PI3K, Akt, and mTOR inhibitors is essential for advancing cancer therapy.
  • Optimizing combination strategies will be key to developing effective treatments for diverse oncology indications.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...